In the CpG+OX40 aptamer+PD1 aptamer group, the percentage of animals having a tumor at the treatment site was 2.5 times smaller than that in the CpG+OX40 aptamer group (Fig. 5B), while the average tumor size on day 20 was 30 times smaller, compared with the group that received no PD1 aptamers (Fig. 5A). Here, TNFRSF4 is linked to neoplasm.